Coated (e.g., Microcapsules) Patents (Class 424/490)
-
Patent number: 11813289Abstract: The invention provides compositions and methods that comprise encapsulated silver diamine fluoride or other antimicrobial materials for use in treatment of dental caries, for example.Type: GrantFiled: April 5, 2019Date of Patent: November 14, 2023Assignee: ADVANTAGE SILVER DENTAL ARREST, LLCInventors: Peter M. Milgrom, Jong Seto
-
Patent number: 11807553Abstract: Decontamination of water using guar gum (GG) derivatives and applications thereof are provided herein. For water decontamination, guar gum cinnamate (GGCi) is fabricated into nanoparticles having a high surface area that facilitates the removal of water pollutants by adsorption. Owing to its high availability, low cost, slow biodegradability and high sustainability, GG is considered promising as a next generation cost effective green material for water decontamination.Type: GrantFiled: April 24, 2023Date of Patent: November 7, 2023Assignee: KING FAISAL UNIVERSITYInventors: Nagaraja Sreeharsha, Anroop B. Nair, Mahesh Attimarad, Katharigatta N. Venugopala, Bandar Aldhubiab, Sonia Kundu, Aalok Basu, Suvadra Das, Partha Roy, Teeka Sathiesh Roopashree
-
Patent number: 11806433Abstract: Described herein are alcohol-resistant oral pharmaceutical compositions and dosage forms that exhibit reduced drug release in the presence of alcohol. The compositions comprise a substrate comprising a controlled release formulation of lorazepam and an alcohol-resistant coating surrounding the substrate.Type: GrantFiled: October 25, 2018Date of Patent: November 7, 2023Assignee: EDGEMONT PHARMACEUTICALS, LLC TRUSTInventors: Douglas Saltel, Michael Vachon
-
Patent number: 11793758Abstract: The disclosure relates, among others, to methods for preparing pharmaceutical compositions that can be provided to the subject in oral form, comprising as an active ingredient: a protein with a mass of 10 kilodalton or more, a nucleic acid molecule of 15 nucleotides or more, or a combination thereof. The one or more active ingredients are distributed in particles in a way that facilitates the uptake of the particles by the intestine and the release of the active ingredient(s) into the blood stream.Type: GrantFiled: June 21, 2019Date of Patent: October 24, 2023Assignee: Bioralix B.V.Inventors: Bernardus Rademaker, Willem Adriaan Minnaard, Eduard Johannes Van Zwieten, Jacob Wieling
-
Patent number: 11793747Abstract: Self-regulating, osmotic, floating gastroretentive compositions that provide extended release, delayed release, and/or delayed extended release of active pharmaceutical agents, as well as, optionally, immediate release of the same or a different active pharmaceutical agent, are provided here. The gastroretentive compositions of the disclosure comprise a swellable, extended release, multilayer core comprising a push layer and a pull layer; a water-insoluble permeable elastic membrane surrounding the multilayer core; and an orifice (e.g., a laser-drilled orifice, a manually drilled orifice) on the pull-layer side of the dosage form. The gastric retention of the composition is controlled by rapid floating of the composition and expansion of the membrane.Type: GrantFiled: October 18, 2021Date of Patent: October 24, 2023Inventors: Navnit H. Shah, Dipen Desai, Wantanee Phuapradit, Jaydeep Vaghashiya, Kanji Meghpara
-
Patent number: 11763451Abstract: The disclosure describes imaging and therapy techniques comprising nanodroplets. More particularly, aspects of the disclosure relate to the use of nanodroplets to modify nanobubbles or microbubbles to provide improved imaging and/or therapeutic techniques and compositions.Type: GrantFiled: May 13, 2022Date of Patent: September 19, 2023Assignee: The Board of Regents of The University of Texas SystemInventors: Robert F. Mattrey, Caroline De Gracia Lux, Jacques Lux, Zhenghong Gao, Carlos J. Brambila
-
Patent number: 11759445Abstract: The present disclosure relates to use of Rivastigmine in the preparation of an anti-radiation medicament, and belongs to the field of medical technology. The present disclosure provides use of Rivastigmine in the preparation of an anti-radiation medicament. Researches show that Rivastigmine significantly promoted the proliferation of Lgr5+ stem cells receiving 10 Gy radiation (after being irradiated with 10 Gy radiation for 10 d, Lgr5+ stem cells cultured in a Rivastigmine-containing culture solution had an increment 14.2 times of that of the Lgr5+ stem cells cultured in a Rivastigmine-free culture solution). Rivastigmine also significantly reduced the mortality of mice after being irradiated with 10 Gy radiation (after receiving 10 Gy whole body irradiation, all the mice not intraperitoneally injected Rivastigmine died within 10 d; and for the mice intraperitoneally injected Rivastigmine, the survival rate of the mice was still greater than 40% 30 d later), and thus might have good radiation-proof effect.Type: GrantFiled: July 29, 2021Date of Patent: September 19, 2023Assignee: SOOCHOW UNIVERSITYInventors: Qiu Chen, Fengmei Cui, Hongbin Yan
-
Patent number: 11752173Abstract: Provided are a modified mesenchymal stem cell and culture supernatant thereof, and a pharmaceutical composition comprising said cell or culture supernatant thereof. The mesenchymal stem cell is capable of expressing: (1) a first protein, which is selected from FGF21 or a variant thereof, or a first fusion protein comprising the FGF21 or the variant thereof and (2) a second protein, which is selected from GLP-1 or a variant thereof or a second fusion protein comprising the GLP-1 or the variant thereof. Also provided is the use of the modified mesenchymal stem cell and culture supernatant thereof, and the pharmaceutical composition comprising said cell or culture supernatant thereof in the treatment of metabolic diseases and in the preparation of a medicament for treating metabolic diseases.Type: GrantFiled: April 2, 2018Date of Patent: September 12, 2023Assignee: Beijing Jiyuan Biological Technology Co., Ltd.Inventors: Haifeng Duan, Binghua Xue, Jing Xie, Zhenli Zhang
-
Patent number: 11753485Abstract: The present application relates to polymer microparticle-metal nanoparticle composites, to methods of preparing polymer microparticle-metal nanoparticle composites and to uses of such composites. The methods comprise introducing into a microfluidic device, a composition comprising: a cationic metal nanoparticle precursor; a polymer microparticle precursor that comprises a plurality of photopolymerizable groups; and a photoreducer-photoinitiator; then irradiating the composition under conditions to simultaneously reduce the cationic metal and polymerize the photopolymerizable groups to obtain the composite.Type: GrantFiled: September 25, 2018Date of Patent: September 12, 2023Assignee: National Research Council of CanadaInventors: Lidija Malic, Xuefeng Zhang, Keith Morton, Teodor Veres
-
Patent number: 11753483Abstract: There is provided a method for producing hydroxypropyl methyl cellulose acetate succinate (HPMCAS), including an esterification step of reacting hydroxypropyl methyl cellulose with an acetylating agent and a succinoylating agent in the presence of an aliphatic carboxylic acid in a kneader reactor equipped with two or more stirring blades rotating around their own axes and orbitally revolving, to obtain a reaction product solution containing HPMCAS; a precipitation step of precipitating the HPMCAS by mixing the reaction product solution with water to obtain a suspension of the precipitated HPMCAS; and a washing and recovery step of washing the HPMCAS in the suspension and recovering the washed HPMCAS. Further, there is provided HPMCAS having yellowness at 20° C. of 15.0 or less, as determined in a 2% by mass solution of the HPMCAS in a mixed solvent of dichloromethane, methanol and water in a mass ratio of 44:44:10.Type: GrantFiled: October 29, 2020Date of Patent: September 12, 2023Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Taishi Kitaguchi, Junichi Matsubara, Mitsuhiro Yoshida
-
Patent number: 11730753Abstract: The present invention relates to pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride. More particularly, the present invention relates to a tablet composition comprising trifluridine, tipiracil hydrochloride and one or more pharmaceutically acceptable excipients and process for preparing such compositions.Type: GrantFiled: March 2, 2019Date of Patent: August 22, 2023Assignee: Natco Pharma LimitedInventors: Tripuraneni Rama Swamy Chowdary, Bhavanasi Krishna Murthy, Yedluri Siddhartha, Bhat Pavan, Nannapaneni Venkaiah Chowdary
-
Patent number: 11723875Abstract: A water-soluble polyurethane derived from: polyethylene glycol, polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol polymer, polypropylene glycol-block-polyethylene glycol-block-polypropylene and mixtures thereof, 1,1?-Carbonyldiimidazole, polyamine and mixtures thereof.Type: GrantFiled: March 26, 2019Date of Patent: August 15, 2023Assignee: The Procter & Gamble CompanyInventors: Travis Kyle Hodgdon, Douglas Michael Graham, Freddy Arthur Barnabas, Corey James Kenneally, Christopher Bryant Williams, Callie Elizabeth Zawaski, Timothy E Long, Allison M Pekkanen, Benjamin Tyler White
-
Patent number: 11707499Abstract: The invention discloses odor masking formulations for stench natural compounds, selected from the extracts, fraction and pure phytochemicals that are produced in combination with a natural or synthetic hydrocolloid polymer gum(s). The invention further discloses novel process of producing the odor and taste masking formulations. The invention also discloses taste masking formulations of valerian extracts with no characteristic stench odor & or negligible stench odor in combination with natural hydrocolloid gum such as guar gum, acacia or other polymers. The invention further discloses method of reducing insomnia, anxiety, Attention Deficit Disorder (ADD), Chronic Fatigue Syndrome (CFS) using odor masking formulation of the current invention. Importantly, the said odor masked formulation of the present disclosure helps in improving sleep cycle and helps in efficient functioning of brain.Type: GrantFiled: September 8, 2017Date of Patent: July 25, 2023Assignee: LAILA NUTRACEUTICALSInventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Kishore Babu Govada, Venkata Krishna Raju Alluri, Nagendra Babu Vutti, Kiran Bhupathiraju, Venkata Kanaka Ranga Raju Gokaraju, Trimurtulu Golakoti
-
Patent number: 11701320Abstract: A mineralization agent, including, by weight: 5-50% of a film-forming protein, 5-40% of an amelogenin peptide, 5-30% of a water-soluble phosphate, 4-20% of a tris(2-carboxyethyl) phosphine hydrochloride, and 1-10% of a pH regulator. The film-forming protein is selected from the group consisting of lysozyme, bovine serum protein, insulin, ?-lactalbumin, or a mixture thereof.Type: GrantFiled: June 30, 2021Date of Patent: July 18, 2023Assignee: MEIYOU (XI'AN) BIOTECHNOLOGY CO., LTD.Inventors: Peng Yang, Dong Wang
-
Patent number: 11696893Abstract: The present invention aims to provide a preparation expected to improve the bitter taste of an organic acid salt of vonoprazan and permit rapid dissolution of the organic acid salt of vonoprazan after administration. The present invention provides a preparation containing fine granules or granules containing (1) a core granule containing an organic acid salt of vonoprazan, (2) an intermediate layer containing the same organic acid as the organic acid forming the salt of vonoprazan in (1), or a salt thereof, and (3) a coating layer containing a water-insoluble polymer.Type: GrantFiled: July 9, 2018Date of Patent: July 11, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Hiroyuki Fujii, Akira Suzuki
-
Patent number: 11690863Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: July 4, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Patent number: 11679068Abstract: Ultraviolet radiation sun protective compositions are reported which feature micronized metal oxide inorganic particles selected from zinc oxide, titanium dioxide and mixtures thereof, the inorganic particles being coated with an adduct of a hydroxy cinnamate and a silanol, amounts of the adduct to the inorganic particles being in a relative weight ratio of 1:200 to 1:4.Type: GrantFiled: August 31, 2018Date of Patent: June 20, 2023Assignee: VIZOR, LLCInventors: Yannick Rigg, Richard Rigg
-
Patent number: 11679168Abstract: Embodiments of the synthesis, radiolabeling and biological applications of an activatable tracer that undergoes intramolecular cyclization and aggregation upon activation by cleavage of a blocking moiety are provided. The probes of the disclosure allow for target-controlled self-assembly of small molecules in living subjects for imaging and drug delivery. The aggregated nanoprobes of the disclosure may be detectable optically, by PET detection, magnetic resonance imaging, and the like depending on the detectable reporter attached to the nanoprobe.Type: GrantFiled: September 13, 2019Date of Patent: June 20, 2023Assignee: The Board of Trustees of Leland Stanford Junior UniversityInventors: Jianghong Rao, Yunfeng Cheng, Min Chen, Jianghang Xie, Zixin Chen
-
Patent number: 11672765Abstract: In one aspect, the present disclosure provides microparticles that are configured to release a first drug over a first time period and to release a second drug over a second time period, wherein a lag period of substantially no drug release occurs between the first and second time periods. In other aspects, the present disclosure pertains to the use of such microparticles in delivery systems and methods of treatment. In another aspect, the present disclosure pertains to drug delivery systems that comprising a folded inflatable drug delivery balloon that comprises folds and microparticles positioned within the folds.Type: GrantFiled: December 2, 2020Date of Patent: June 13, 2023Assignee: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Javier Palomar-Moreno, Michelle Hannon, Phillip Bannister
-
Patent number: 11666538Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.Type: GrantFiled: October 4, 2022Date of Patent: June 6, 2023Assignee: Impax Laboratories, LLCInventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
-
Patent number: 11660331Abstract: An improved heroin conjugate vaccine is detailed; to accomplish this task the systematic exploration of twenty vaccine formulations with varying combinations of carrier proteins and adjuvants were undertaken. In regard to adjuvants, a Toll-like receptor 9 (TLR9) agonist and a TLR3 agonist in the presence of alum were explored. The vaccine formulations containing TLR3 or TLR9 agonist alone-elicited strong anti-heroin antibody titers and blockade of heroin-induced antinociception when formulated with alum; however, a combination of TLR3 and 9 adjuvants did not result in improved efficacy. Investigation of stability of the two lead formulations revealed that the TLR9 but not the TLR3 formulation was stable when stored over 30 days. Furthermore, mice immunized with the TLR9+alum heroin vaccine gained significant protection from lethal heroin doses, suggesting that this vaccine formulation is suitable for mitigating the lethal effects of heroin, even following long-term storage at room temperature.Type: GrantFiled: November 8, 2018Date of Patent: May 30, 2023Assignee: The Scripps Research InstituteInventor: Kim D. Janda
-
Patent number: 11648206Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.Type: GrantFiled: October 7, 2019Date of Patent: May 16, 2023Assignee: MURRAY AND POOLE ENTERPRISES LTDInventor: Susanne Riel
-
Patent number: 11648569Abstract: The present invention relates to the use for ore beneficiation, of at least one derivative of alkoxylated (polyester)amine. The present invention also relates to the flotation pulp and the tailings comprising said product useful for ore beneficiation.Type: GrantFiled: February 13, 2017Date of Patent: May 16, 2023Assignee: Arkema FranceInventors: Eric Jorda, Alain Baloche, Nathalie Gibert, Isabelle Birken, Gilles Barreto, Jean-Paul Gamet
-
Patent number: 11634604Abstract: Loose particulate materials can be problematic in various aspects. For example, loose particulate materials may generate dust or be difficult to consolidate together. Fines in loose particulate materials may also be an issue. Coated particulates may alleviate some of the foregoing issues. Suitable coated particulates may comprise a particulate material comprising sand or a ceramic, and a polysaccharide composition coated upon the particulate material, the polysaccharide composition comprising a functionalized polysaccharide. Other particulate materials such as wood chips and animal litter particulates may be coated with functionalized polysaccharides to achieve similar advantages.Type: GrantFiled: March 7, 2018Date of Patent: April 25, 2023Assignee: Integrity Bio-Chemicals, LLCInventors: Ashoka V. R. Madduri, Christopher P. Gardner, Sanket Gandhi, Matthew B. Blackmon, Charles R. Landis, Curtis J. Rodencal
-
Patent number: 11633447Abstract: A composition according to an embodiment of the present disclosure includes a banaba leaf extract, a guava leaf extract or a mixture thereof. The composition inhibits photooxidation of A2E due to blue light, inhibits a death of retinal pigment epithelial cells induced by blue light, and inhibits a damage to outer nuclear layers of visual cells in an animal model with blue light-induced macular degeneration, and thus can be beneficially used as a composition for preventing or treating macular degeneration and as a health functional food for preventing or alleviating macular degeneration.Type: GrantFiled: July 9, 2019Date of Patent: April 25, 2023Assignee: LEMONEX INC.Inventors: Cheol Hee Won, Jun Kim
-
Patent number: 11622941Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.Type: GrantFiled: July 10, 2021Date of Patent: April 11, 2023Assignee: Impax Laboratories, LLCInventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
-
Patent number: 11612592Abstract: Liquid formulations containing picosulfate and magnesium citrate are provided. The compositions can include one or more precipitation inhibitors such as carboxylic acids (e.g., malonic acid), soluble anionic polymers and ammonium salts. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.Type: GrantFiled: August 16, 2016Date of Patent: March 28, 2023Assignee: FERRING B.V.Inventors: Alfred Chi-Yeh Liang, Nipul Ghanshyambhai Patel, Jian-Xin Li
-
Patent number: 11607420Abstract: The present invention relates to a new formulation of specific nutritional ingredients (nutraceuticals) and/or pharmaceutical compounds.Type: GrantFiled: June 6, 2019Date of Patent: March 21, 2023Assignee: DSM IP ASSETS B.V.Inventors: Elger Funda, Odile Krainz
-
Patent number: 11596645Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: GrantFiled: October 27, 2021Date of Patent: March 7, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Patent number: 11596669Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.Type: GrantFiled: March 10, 2022Date of Patent: March 7, 2023Assignee: 89BIO, INC.Inventors: Boris Schwartsburd, Shaji Joseph
-
Patent number: 11583497Abstract: The invention provides ocular formulations and features a nano-emulsion composition, e.g., a nano-emulsion comprising a CBF?-RUNX1 inhibitor. The composition comprises a particle with a length of less than 200 nanometers in at least one dimension.Type: GrantFiled: November 14, 2018Date of Patent: February 21, 2023Assignee: The Schepens Eye Research Institute, Inc.Inventors: Leo A. Kim, Joseph F. Arboleda-Velasquez
-
Patent number: 11576886Abstract: The present invention relates to a construct comprising a C13 to C27 fatty acid non-covalently bound to a hydrophobic region of a carrier particle, methods of manufacture, and uses thereof.Type: GrantFiled: November 13, 2018Date of Patent: February 14, 2023Assignee: Polyrem LimitedInventors: Tony Davies, Deirdre McIntosh, Malcolm Weetman
-
Patent number: 11564888Abstract: The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising organic acid that is coated with at least one drug layer comprising trihexyphenidyl hydrochloride, and a functional coat over the drug-layered core. The extended release compositions of the disclosure provide extended release of trihexyphenidyl hydrochloride, with reduced Cmax, and a Cmin:Cmax ratio of ?0.4, while maintaining a therapeutically effective concentration for a period of at least about 16 hours. The compositions of the disclosure improve solubility of trihexyphenidyl hydrochloride, at a pH of greater than or equal to 5, to maintain its minimum effective concentration at such pH.Type: GrantFiled: September 19, 2019Date of Patent: January 31, 2023Assignee: Amneal Complex Products Research LLCInventors: Namdev B. Shelke, Siva Ram Kiran Vaka, Navnit H. Shah, Dipen Desai, Wantanee Phuapradit
-
Patent number: 11559494Abstract: In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.Type: GrantFiled: July 13, 2018Date of Patent: January 24, 2023Assignee: THE PENN STATE RESEARCH FOUNDATIONInventors: Daniel J Hayes, Mohammad Abu-Laban
-
Patent number: 11534406Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: March 18, 2020Date of Patent: December 27, 2022Assignee: Tillotts Pharma AGInventors: Felipe José Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 11524072Abstract: A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.Type: GrantFiled: October 2, 2020Date of Patent: December 13, 2022Assignee: University of Georgia Research Foundation, Inc.Inventors: Donald A. Harn, Rafaella Queiroz, Lisa Shollenberger, Emily-Joy Farah Samli
-
Patent number: 11517534Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: June 2, 2017Date of Patent: December 6, 2022Assignee: Tillotts Pharma AGInventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 11517588Abstract: The present disclosure provides a nanoparticle, a preparation process thereof, a method for treating cancer, a method for enhancing effect of a liver cancer drug, a method for ameliorating tumor hypoxia, and a method for enhancing effect of a liver cancer vaccine by using the nanoparticle.Type: GrantFiled: June 23, 2020Date of Patent: December 6, 2022Assignee: NATIONAL TSING HUA UNIVERSITYInventors: Yun-Ching Chen, Tsai-Te Lu, Yun-Chieh Sung
-
Patent number: 11517610Abstract: A bone repair material, a preparation method of the bone repair material, and a biological composite scaffold are provided. The bone repair material includes: a base material, and a carbon nanomaterial and a polypeptide both mixed with the base material; and the carbon nanomaterial and the polypeptide are bonded by chemical bonds. The preparation method includes: bonding a carbon nanomaterial with a polypeptide by chemical bonds; and mixing the carbon nanomaterial and the polypeptide bonded by the chemical bonds with a base material, and performing a molding treatment.Type: GrantFiled: June 21, 2019Date of Patent: December 6, 2022Assignee: BEIJING BOE TECHNOLOGY DEVELOPMENT CO., LTD.Inventors: Tianxiao Zhao, Zhichao Li, Changjun Liu, Xianzhen Li, Tianyue Zhao
-
Patent number: 11504431Abstract: Provided herein are fluid formulations for administration to a suprachoroidal space of an eye of a patient. The fluid formulations may include a pharmaceutical agent, a binding molecule, or a combination thereof. The pharmaceutical agent and the binding molecule may be bonded to each other covalently, non-covalently, or a combination thereof. The pharmaceutical agent may be configured to bond to an ocular tissue. The binding molecule may be configured to bond to an ocular tissue. Methods of administering the fluid formulations, methods of expanding a suprachoroidal space, and methods of reducing the minimum force to separate the sclera and choroid are provided.Type: GrantFiled: July 20, 2017Date of Patent: November 22, 2022Assignees: Emory University, Georgia Tech Research CorporationInventors: Mark R. Prausnitz, Bryce Chiang
-
Patent number: 11504337Abstract: The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.Type: GrantFiled: July 18, 2019Date of Patent: November 22, 2022Assignee: ModernaTX, Inc.Inventors: Paolo Martini, Vladimir Presnyak, Kerry Benenato, Stephen Hoge, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe
-
Patent number: 11478505Abstract: Provided herein are compositions comprising ixabepilone, or a pharmaceutically acceptable salt thereof, and a copolymer represented by formula I: Also provided are methods of treating cancer using the compositions described herein, and methods of preparing the compositions.Type: GrantFiled: January 8, 2021Date of Patent: October 25, 2022Assignee: R-Pharm US Operating LLCInventors: Kevin N. Sill, Bradford T. Sullivan
-
Patent number: 11471564Abstract: An object of the present invention is to provide an angiogenic agent that can sufficiently exhibit an angiogenic effect due to mesenchymal stem cells in a state where the angiogenic agent does not allow permeation of host cells while being protected from immune rejection, and a method for method for manufacturing the same. According to the present invention, an angiogenic agent including a mesenchymal stem cell (A); and an immunoisolation membrane (B) that encloses the mesenchymal stem cell is provided.Type: GrantFiled: February 28, 2020Date of Patent: October 18, 2022Assignee: FUJIFILM CorporationInventors: Kentaro Nakamura, Ryo Kogawa
-
Patent number: 11464811Abstract: A production method of microencapsulated probiotics with chitosan-alginate polymers, the microcapsules loaded with probiotics obtained by this method and their use in food, agriculture and cosmetics. The microcapsules do not make alterations in the color and appearance of the product in which they are applied and have antifungal and anti-mycotoxin features.Type: GrantFiled: August 15, 2018Date of Patent: October 11, 2022Assignee: NANOMIK BIYOTEKNOLOJI A.S.Inventor: Buse Berber
-
Patent number: 11464740Abstract: Methods and monodisperse glass microsphere composites comprising a porous wall hollow-glass microsphere; a cargo of a therapeutic is loaded inside of the porous wall hollow-glass microsphere; and a first shell fully encapsulating the porous wall hollow-glass microsphere and capping pores in the walls, retaining the cargo inside of the porous wall hollow-glass microsphere.Type: GrantFiled: April 29, 2020Date of Patent: October 11, 2022Assignees: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE, MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, APPLIED RESEARCH CENTER, INC.Inventors: Paul M. Weinberger, George Wicks, William D. Hill
-
Patent number: 11458133Abstract: Disclosed herein are methods for treating solid tumors by direct injection into the tumors of chemotherapeutic particles, methods for inhibiting tumor metastasis by administering chemotherapeutic particles to a subject having a tumor, and compositions that include chemotherapeutic particles, small amounts of a polysorbate, and a carrier.Type: GrantFiled: April 3, 2020Date of Patent: October 4, 2022Assignee: CritiTech, Inc.Inventors: Mike Baltezor, Gere diZerega, Charles Decedue, Sam Campbell, Matt McClorey
-
Patent number: 11458112Abstract: Methods, pharmaceutical formulations, and kits are provided for using capsaicin to effectuate voluntary defecation in mammals who cannot defecate without external invasion of the bowel or those who defecate involuntarily (i.e., those having fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing defecation in mammals that do not have defecation dysfunction such as, for example, in a person who is unconscious and may defecate unconsciously or in a pet at a convenient location at a specific time. The methods and compositions provide patients with defecation dysfunction control over when and where they defecate.Type: GrantFiled: January 29, 2020Date of Patent: October 4, 2022Assignee: DIGNIFY THERAPEUTICS, LLCInventors: Karl Bruce Thor, Lesley Marson
-
Patent number: 11458153Abstract: This invention discloses drug-delivery compositions, methods of making prodrugs, and methods of drug delivery using a self-assembled gelator. The backbone of the gelator can contain a drug or prodrug, such as acetaminophen or salicin. Additional drugs or agents can be encapsulated in the gelator. Enzymatic or hydrolytic cleavage can be used to release the drugs.Type: GrantFiled: July 18, 2016Date of Patent: October 4, 2022Assignees: The City University of New York, represented by The Research Foundation of the City University of New York, The Brigham and Women's Hospital Inc.Inventors: Jeffrey M. Karp, Praveen Kumar Vemula, George John, Greg Cruikshank
-
Patent number: 11446245Abstract: Provided is a composition including a first phase comprising a first filler; a second phase, the second phase comprising a second filler; and a third phase comprising a third filler; and a fourth phase comprising a fourth filler; and a first active ingredient, wherein the first active ingredient is selected from the group consisting of caffeine, Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Acmella oleracea, Helichrysum umbraculigerum, Radula marginata, kava, kanna, black truffle, Syzygium aromaticum, Rosmarinus oficinalis, basil, oregano, lavender, true cinnamon, malabathrum, cananga odorata, Riboflavin, theanine, Ginkgo Biloba, Bacopa, Rhodiola Rosea, and combinations thereof.Type: GrantFiled: January 29, 2021Date of Patent: September 20, 2022Assignee: NULIXIR INC.Inventor: Ehsan Moaseri
-
Patent number: 11427661Abstract: The present invention provides a fluorescent polymer comprising a fluorophore perylene bisimide (PBI) and oligo (p-phenylene vinylene) (OPV) functionalized with carboxy and amine functionality groups and a polystyrene (PS) backbone for the detection of volatile organic compound, a process for the detection and a kit thereof.Type: GrantFiled: February 18, 2019Date of Patent: August 30, 2022Assignee: Council of Scientific & Industrial ResearchInventors: Sarabjot Kaur Makkad, Asha Syamakumari